Objective: The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD). Method: Eleven subjects (10 males) with TD (age 9-19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label, flexible-dosing study over 10 weeks. Tic severity was rated using the Yale Global Tic Severity Scale (YGTSS) and the Clinical Global Impressions Scale for tics (CGI-Tics) at baseline and at follow-up. Results: The mean (AESD) daily dose for aripiprazole was 4.5 AE 3.0 mg. Mean (AESD) YGTSS Global Severity scores reduced from 61.82 AE 13.49 at baseline to 33.73 AE 15.18 at end point; mean YGTSS total tic scores reduced from 28.18 AE 7.74 at baseline to 16.73 AE 7.54 at end point. Mean (AESD) CGI-Tic severity scores reduced from 4.45 AE 0.52 (moderate-marked) at baseline to 3.18 AE 0.60 (mild) at end point. On the CGI-Tic improvement scale, 10 (

No abstract

No abstract

No abstract